TG Therapeutics, Inc. (TGTX)
NASDAQ: TGTX · Real-Time Price · USD
35.07
+0.52 (1.51%)
At close: Nov 22, 2024, 4:00 PM
35.23
+0.16 (0.46%)
After-hours: Nov 22, 2024, 6:59 PM EST
TG Therapeutics Revenue
TG Therapeutics had revenue of $83.88M in the quarter ending September 30, 2024, a decrease of -49.41%. This brings the company's revenue in the last twelve months to $264.79M, up 39.53% year-over-year. In the year 2023, TG Therapeutics had annual revenue of $233.66M with 8,290.02% growth.
Revenue (ttm)
$264.79M
Revenue Growth
+39.53%
P/S Ratio
19.18
Revenue / Employee
$1,002,992
Employees
264
Market Cap
5.03B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 233.66M | 230.88M | 8,290.02% |
Dec 31, 2022 | 2.79M | -3.90M | -58.36% |
Dec 31, 2021 | 6.69M | 6.54M | 4,300.66% |
Dec 31, 2020 | 152.00K | - | - |
Dec 31, 2019 | 152.00K | - | - |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Oscar Health | 8.22B |
ICU Medical | 2.34B |
Integer Holdings | 1.71B |
Alkermes | 1.51B |
Haemonetics | 1.36B |
Ultragenyx Pharmaceutical | 522.75M |
Axsome Therapeutics | 338.46M |
BridgeBio Pharma | 217.77M |
TGTX News
- 1 day ago - TG Therapeutics Ranked Number One Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™ - GlobeNewsWire
- 17 days ago - TG Therapeutics: Modest Q3 Sales Beat, Focus Shifts To Early 2025 Updates - Seeking Alpha
- 18 days ago - TG Therapeutics Posts Strong Q3 Briumvi Revenue, Here's Why Shares Fell - Seeking Alpha
- 18 days ago - TG Therapeutics, Inc. (TGTX) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 18 days ago - FUJIFILM Diosynth Biotechnologies Signs Manufacturing Supply Agreement with TG Therapeutics - GlobeNewsWire
- 21 days ago - TG Therapeutics to Host Conference Call on Third Quarter 2024 Financial Results and Business Update - GlobeNewsWire
- 2 months ago - TG Therapeutics: A Look At New Briumvi Data And Ocrevus Zunovo Approval - Seeking Alpha
- 2 months ago - New BRIUMVI® (ublituximab-xiiy) Data from the ENHANCE Phase 3b Study Show Rapid 30-Minute Infusions are Well Tolerated in Patients with Relapsing Forms of Multiple Sclerosis - GlobeNewsWire